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Varicella-zoster virus (VZV) is the etiological agent of chickenpox and shingles. Due to the virus’s restricted host and cell type
tropism and the lack of tools for VZV proteomics, it is one of the least-characterized human herpesviruses. We generated 251
monoclonal antibodies (MAbs) against 59 of the 71 (83%) currently known unique VZV proteins to characterize VZV protein
expression in vitro and in situ. Using this new set of MAbs, 44 viral proteins were detected by Western blotting (WB) and indi-
rect immunofluorescence (IF); 13 were detected by WB only, and 2 were detected by IF only. A large proportion of viral proteins
was analyzed for the first time in the context of virus infection. Our study revealed the subcellular localization of 46 proteins, 14
of which were analyzed in detail by confocal microscopy. Seven viral proteins were analyzed in time course experiments and
showed a cascade-like temporal gene expression pattern similar to those of other herpesviruses. Furthermore, selected MAbs
tested positive on human skin lesions by using immunohistochemistry, demonstrating the wide applicability of the MAb collec-
tion. Finally, a significant portion of the VZV-specific antibodies reacted with orthologs of simian varicella virus (SVV), thus
enabling the systematic analysis of varicella in a nonhuman primate model system. In summary, this study provides insight into
the potential function of numerous VZV proteins and novel tools to systematically study VZV and SVV pathogenesis.
Varicella-zoster virus (VZV) belongs to the alphaherpesvirussubfamily and is the only member of the genus Varicellovirus
that can infect humans (1, 2). Primary infection causes chicken-
pox and typically occurs in early childhood with a prominent,
highly contagious vesicular rash (3). During primary infection,
VZV establishes latency in sensory trigeminal and dorsal root gan-
glia. Reactivation from latency results in a secondary disease called
herpes zoster (HZ), or shingles, that is more common in elderly
people (4). HZ most frequently occurs in the thoracic or lumbar
nerve segments and the distribution area of the trigeminal nerve,
causing a painful rash in the corresponding dermatome.While the
molecular mechanism for reactivation from latency is not well
characterized, it is more frequent in immunocompromised pa-
tients (5). The most common sequela of HZ is postherpetic neu-
ralgia (PHN). In addition, VZV reactivation can lead to zoster
ophthalmicus, acute retinal necrosis, meningitis, and vasculopa-
thy (6).
The seroprevalence of VZV differs significantly between coun-
tries, but themajority of individuals are seropositive by the time of
adolescence (7). While in otherwise healthy children and adoles-
cents, primaryVZV infectionmostly resolves spontaneouslywith-
out sequelae, severe symptoms may occur in immunocompro-
mised people and during pregnancy (6). Vertical transmission of
VZV during the first trimester causes congenital varicella syn-
drome (CVS), which is characterized by skin lesions, hypoplasia,
low birth weight, and neurological disorders, while perinatal in-
fection at the time of delivery leads to neonatal varicella, with high
morbidity and mortality rates. Chickenpox and shingles vaccines
based on the live-attenuated VZV v-Oka strain have been devel-
oped, and the former has been introduced into childhood immu-
nization schemes in several countries (8). However, the increased
incidence of HZ-related complications within the expanding el-
derly population calls for more effective ways to prevent primary
infection with VZV and to limit reactivation from latency.
With a genome of approximately 125,000 bp containing 74
open reading frames (ORFs), 3 of which are duplicated (ORF62/
71, ORF63/70, and ORF64/69), leaving 71 unique ORFs, VZV is
the smallest human herpesvirus (9–11). A recent report in which
the genomewas systematicallymutagenized determined that 44 of
71VZVORFs are essential for viral replication (12). VZV contains
5 unique genes (ORF1, ORF2, ORF13, ORF32, and ORF57) not
present in herpes simplex virus 1 (HSV-1) and lacks 15 genes
expressed by HSV-1 (9, 11, 13). Like all herpesviruses, the VZV
virion consists of a nucleocapsid that harbors the double-stranded
DNA genome surrounded by a tegument protein layer and a host-
derived plasma membrane called the envelope, containing viral
glycoproteins. Nucleocapsids formed in the infected nucleus are
thought to gain access to the cytoplasm by budding through the
nuclear envelope and receive their secondary envelope at the
trans-Golgi network (TGN). Considering the high infectivity of
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VZV virions released from cutaneous lesions, it is surprising that
in vitroVZVpropagation is highly cell associated. This is caused at
least in part by diversion of newly formed virions from the TGN to
late endosomes (14). VZV infection is restricted to humans, and
consequently, an appropriate animal model is lacking. Experi-
mental inoculation of mice, rats, and nonhuman primates with
VZV leads to seroconversion but not to disease resembling chick-
enpox andherpes zoster (15). This limitation is partially overcome
by a SCID-humanizedmousemodel inwhich fetal human tissue is
grafted and subsequently infected with VZV (16). More recent
research revealed that infection of nonhuman primates with sim-
ian varicella virus (SVV) recapitulatesmost features of VZV infec-
tion in humans (3, 17–19). SVV is a member of the Varicellovirus
genus along with VZV, equine herpesvirus 1 (EHV-1), EHV-4,
pseudorabies virus (PRV), Marek’s disease virus (MDV), and bo-
vine herpesvirus 1 (BHV-1). Monkeys infected with SVV develop
an exanthemamimicking chickenpox, which is spontaneously re-
solved, leading to latency in ganglia along the entire neuroaxis as
well as the induction of SVV-specific B- and T-cell responses
(17–19).
Due to its highly cell-associated character in vitro as well as the
lack of appropriate animal models and virus-specific tools such as
monoclonal antibodies (MAbs), many aspects of the VZV life cy-
cle are currently still poorly understood. Previously, only 8mono-
clonal and 29 polyclonal antibodies against 37 VZV proteins were
described. To provide these tools and to be able to further inves-
tigate the molecular pathogenesis of VZV, we used a VZV ORF
clone collectionmade recently (20–23) to generate a genome-scale
MAb collection that was subsequently used to perform a compre-
hensive analysis of VZV proteins.
MATERIALS AND METHODS
Viruses and cells.Uninfected and infectedMeWohumanmelanoma cells
(ATCC HTB-65) and the ARPE-19 human retinal pigment epithelial cell
line (ATCC CRL-2302) were cultured in Dulbecco’s modified Eagle me-
dium (DMEM) supplemented with 10% fetal calf serum (FCS), L-glu-
tamine, and antibiotics. To generate stable mouse hybridomas, SP2/O
myeloma cells (ATCC CRL 1581) cultured in supplemented or plain
RPMI 1640 medium were used. The VZV pOKA strain was used as the
PCR template and for all infections (24). VZV was propagated by adding
pOKA-infected MeWo cells to uninfected MeWo cells at a ratio of 1:50.
Cell-free VZV strain EMC-1was obtained as described previously (25, 26)
and used for the infection of ARPE-19 cells. Telomerized rhesus fibro-
blasts (TRFs) were maintained in DMEM supplemented with 10% FCS
and antibiotics. The recombinant SVV delta, in which enhanced green
fluorescent protein (eGFP) was inserted between US2 and US3 through
homologous recombination (27), was propagated on TRFs by inoculating
uninfected cells with SVV-infected TRFs at a ratio of 1:10.
Generation of expression vectors. An ORFeome-wide pOKA VZV
entry library that was previously generated by using Gateway recombina-
tional cloning (20) was subcloned into pETG-based vectors encoding N-
terminally 6His-, C-terminally 6His-, or N-terminally maltose-bind-
ing protein (MBP)-tagged proteins. T7-driven expression of VZV
proteins was performed in Escherichia coli BL21(DE3) and Rosetta DE3
cells. For baculovirus-based expression, VZV ORFs were subcloned into
the DEST10 vector, providing an N-terminal 6His tag (Invitrogen), by
using the Gateway recombinational system.
Protein expression and purification. BL21(DE3) and Rosetta DE3
cells were used for bacterial expression of 6His- or MBP-tagged VZV
proteins. Twentymilliliters of a culture of BL21(DE3) or RosettaDE3 cells
transformed with expression vectors encoding VZV ORFs and grown
overnight was inoculated into 1 liter of selective LBmedium (50g/ml of
ampicillin, 50 g/ml of chloramphenicol) and grown at 37°C until an
optical density at 600 nm (OD600) of 0.6 was reached. Protein expression
was induced by addition of 1 mM isopropyl--D-thiogalactopyranoside
(IPTG) and further shaking of the culture for 4 to 6 h at 37°C. Alterna-
tively, proteins were produced by using the baculovirus system essentially
according to the manufacturer’s protocol (Invitrogen). In brief, to recon-
stitute baculovirus, Sf9 cells (ATCC CRL-1711) were seeded into 6-well
plates (900,000 cells/well), incubated at 27°C for 2 h, and transfected with
DEST10 containing VZV ORF coding sequences (1 g/well) and Cellfec-
tin reagent (6 l). Cells were maintained in Grace’s insect cell culture
medium either nonsupplemented for transfection or supplemented for
cell growth. Three days later, the supernatant containing reconstituted
virus was collected (P1 virus stock) and used to generate the P2 virus stock
on Sf9 insect cells. The titration of the P2 stock was done by using serial
dilutions, and baculovirus plaques were counted by using trypan blue.
Protein production was monitored by Western blotting (WB) at 24 h, 48
h, and 72 h postinfection (hpi), usingmultiplicities of infection (MOIs) of
5 and 20.
To generate cell lysates, bacterial cells or baculovirus-infected cells
were harvested, resuspended in 40ml of lysis buffer (50mMTris-HCl [pH
6.8], 0.3MNaCl, 6M guanidinium hydrochloride, and 5mM imidazole),
and lysed by sonication. Soluble proteins were recovered by centrifuga-
tion and incubated with 1 ml of preequilibrated Ni-nitrilotriacetic acid
(NTA) agarose beads. Following incubation of the protein solution for 30
min, the slurry was allowed to drain by gravity and washed extensively
with urea buffer with stepwise increasing concentrations of imidazole (0,
10, and 50mM imidazole). Finally, the proteinwas eluted 3 timeswith 500
l of elution buffer (50mMTris-HCl [pH 6.8], 0.3MNaCl, 4Murea, and
450 mM imidazole). Eluted fractions and samples of solutions were ana-
lyzed by SDS-PAGE and WB.
Generation of monoclonal antibodies. BALB/c mice were injected
subcutaneously with recombinantly expressed protein (50 g) or a pep-
tide conjugated to keyhole limpet hemocyanin (KLH) (50g) in complete
Freund’s adjuvant. Two weeks later, mice were boosted with the same
protein in incomplete Freund’s adjuvant by injecting a two-thirds volume
subcutaneously and a one-third volume intraperitoneally (i.p.). After an
additional 2-week period, the sera of immunized mice were screened for
antibody titers against the immunogen by using an enzyme-linked immu-
nosorbent assay (ELISA). The best responders were additionally boosted
i.p. with the immunogen dissolved in phosphate-buffered saline (PBS).
Three days later, spleen cells were collected and, after lysis of red blood
cells, fusedwith SP2/0myeloma cells at a ratio of 1:1. The cells were seeded
onto 96-well tissue culture plates in 20% RPMI 1640 medium containing
hypoxanthine, aminopterin, and thymidine for hybridoma selection. The
cultures were screened for MAbs reactive against immunogens by using
an ELISA. Positive mother wells were expanded and cloned.
Indirect immunofluorescence. Uninfected and infected MeWo cells
were cultured at a ratio of 50:1 on glass coverslips for 48 h and subse-
quently processed for immunofluorescence (IF) essentially as described
previously (28). Nonspecific binding was blocked by incubating cells for 1
hwith PBS containing 10%goat serumand 0.3%TritonX-100. In the case
of sample preparation for confocal microscopy, 0.2 mg human IgG/ml
(Sigma) and 0.3% Triton X-100 were used for blocking. Cells were incu-
bated for 2 to 3 h at room temperature (RT)withMAb supplementedwith
3% goat serum or human IgG and 0.3% Triton X-100. For confocal mi-
croscopy, antibodies recognizing lamin B (Santa Cruz) and TGN46 (AbD
Serotec) were used in parallel to mark the nuclear envelope and trans-
Golgi network (TGN), respectively. After several washes, the sampleswere
incubated with Alexa 488- or Alexa 594-conjugated secondary reagents
(Invitrogen). Nuclear chromatin was visualized by DAPI (4=,6-di-
amidino-2-phenylindole) staining. Finally, cells were embedded in
mounting medium (Vectashield) and examined by using a Leica fluores-
cence microscope at a magnification of40. Alternatively, an SP5 confo-
cal microscope was used.
Western blot analysis. Total lysates of mock- or pOKA-infected
MeWo cells were separated on 6 to 15% SDS-PAGE gels. Upon transfer
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onto nitrocellulose, membranes were incubated with MAb followed by
goat anti-mouse antibodies conjugated to horseradish peroxidase (Di-
anova). Binding of antibodies was detected by enhanced chemilumines-
cence (ECL) (GE Healthcare). Mock- and SVV-infected TRFs were lysed
at 48 hpi by adding 2 reducing Laemmli sample buffer and cleared by
usingQIAshredder columns (Qiagen). Proteinswere resolved on 6 to 15%
SDS-PAGE gels and transferred onto nitrocellulose membranes, which
were incubated with theMAb followed by goat anti-mouse antibody con-
jugated to horseradish peroxidase (Santa Cruz). Specific staining was de-
tected by ECL (Thermo Scientific). Cell-free VZV was obtained as de-
scribed previously (25, 26). Briefly, ARPE-19 human retinal pigment
epithelial cells were infected with a clinical VZV isolate (EMC-1) and
scraped when the cells showed 30 to 50% cytopathic effect (25, 26). In-
fected cells were sonicated 3 times for 15 s, clarified for 15 min at 1,000
g, and frozen at 80°C until use. For kinetic analysis, 5  105 ARPE-19
cells/well were seeded into 12-well plates and infected with cell-free VZV
EMC-1 (passage 30) at an MOI of 0.12, followed by spin inoculation (20
min at 1,000 g at RT). After incubation of cells at 37°C for 40 min, the
virus inoculum was washed away, and the cells were harvested at the
indicated time points. To prepare lysates, cells were washed with PBS,
trypsinized, spun down, and, after another wash step, lysed in radioim-
munoprecipitation assay (RIPA) buffer containing protease inhibitors
(Roche Applied Science). Western blots were probed with MAbs recog-
nizing VZVORF4, ORF8, ORF18, ORF24, ORF48, ORF63, andORF68 or
an actin-specific MAb to standardize the amount of protein loaded, fol-
lowed by peroxidase-labeled secondary antibodies, and developed by us-
ing a Western blot imaging system (UVItec).
Immunohistology. Punch biopsy specimens of suspected herpes zos-
ter skin lesions were obtained for diagnostic purposes. Control human
skin tissue included was breast skin from a healthy woman undergoing
breast reconstruction. The tissue derived from herpes zoster skin lesions
was confirmed to be VZVDNA positive by successive in-house PCR anal-
yses (29). Punch biopsy specimens were snap-frozen in N2. Frozen skin
sections (6 m thick) were fixed in acetone containing 0.3% hydrogen
peroxide for 10min (30). Sections were stained for VZV proteins by using
the newly developed MAbs directed to VZV ORF4, ORF21, ORF62,
ORF63, and ORF66. Negative and positive controls included appropriate
isotype controls and well-described anti-VZV MAbs directed to VZV
ORF62 (clone 8616; Millipore) and ORF63 (clone 9D12; a generous gift
from C. Sadzot-Delvaux, Liège, Belgium) (31), respectively. Antibody
staining was visualized by using an avidin-biotin complex system (Dako-
Cytomation) and 3-amino-9-ethylcarbazole (AEC; Sigma-Aldrich) as the
substrate. Sections were counterstained with hematoxylin (Sigma-Al-
drich). Study procedures to acquire andprocess the skin biopsy specimens
were performed in compliance with Dutch laws and institutional guide-
lines and in accordance with the ethical standards of the Declaration of
Helsinki.
RESULTS
Generation of monoclonal antibodies against VZV proteins. To
express VZV proteins for immunization, each of the 71 known
and unique ORFs was expressed (i) as a full-length protein and/or
fragment, (ii) with different N- and C-terminal, large and peptide
tags, or (iii) with different expression systems. In summary, 160
plasmid constructs were generated for expression with an N- or
C-terminal His tag (99 full-length constructs and 61 fragments),
and 94 constructs were constructed for expression with an N-ter-
minal MBP tag (65 full-length constructs and 29 fragments) in E.
coli, along with 19 constructs for expression by baculovirus re-
combinants. With this approach, we were able to express 62 dis-
tinct viral proteins in amounts sufficient for immunization of
mice. For an additional six ORFs, which could not be expressed by
using any of the above-mentioned methods, peptides derived
from their primary sequence were used as immunogens to gener-
ateMAbs, as described inMaterials andMethods. In this study, we
generated 251 novel MAbs against 59 of 71 (83%) unique VZV
proteins, including 24 ORFs that are covered exclusively by this
new MAb collection (Fig. 1). This enabled us to perform an ex-
tended analysis of VZV protein expression during lytic infection.
Detection of VZV proteins in lytically infected cells in vitro.
Due to the lack of specific antibodies, expression of numerous
VZV proteins has remained obscure in the context of lytic infec-
tion. Using the new set of 251 VZV-specific MAbs, we validated
theMAbs and determined the molecular weights of VZV proteins
by WB analysis of infected MeWo cell lysates (Fig. 2). A large
number of the 251ELISA-positive hybridoma cloneswere reactive
in WB experiments and detected 57 of 71 (80%) unique VZV
proteins. All MAb-detected proteins were found exclusively in
infected but not in uninfected cell lysates. The scaffold proteins
ORF33 andORF33.5 were recognized by the sameMAb but could
be distinguished by WB according to their molecular weight. In
general, the migration of VZV proteins in SDS-PAGE gels corre-
lated well with the predicted molecular weight, with only few ex-
ceptions. This is probably caused by proteolytic processing, a
highly basic or acidic character, or posttranslationalmodification.
This was particularly evident for the glycoproteins ORF5, ORF31,
ORF37, and ORF60.
Kinetics of VZV protein expression during lytic infection in
vitro.To determine the temporal gene expression level of VZV, an
improved protocol was applied for the production of cell-free
FIG 1 Coverage of the novel VZV-specific monoclonal antibody collection.
To summarize all available antibodies to VZV proteins, several search engines
were applied. Coverage of 71 VZV ORFs by currently available antibodies
(top) and monoclonal antibodies newly generated with our collection (bot-
tom) is presented. In addition, in the top panel, ORFs previously visualized via
tags or fusion proteins are noted.
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VZV that facilitated infectious virus titers of up to 5 105 PFUper
ml (25, 26). Cell-free VZV was used to spin inoculate ARPE-19
cells, a human retinal pigment epithelial cell line, at an approxi-
mate MOI of 0.12. Cell lysates were prepared at 0 to 24 hpi and
analyzed by WB (Fig. 3). Viral ORF4 and ORF63 products were
detected at 6 hpi, as expected for transactivators generally ex-
pressed as immediate early (IE) proteins. Antibodies specific for
proteins encoded by ORF8 (dUTPase), ORF18 (ribonucleotide
reductase, small subunit), and ORF48 (DNase) were detected at
between 8 and 10 hpi, typical for proteins involved in viral DNA
replication at an early (E) phase of viral infection. The ORF24
product, the VZV ortholog of the HSV-1 nuclear egress protein
UL34, was expressed with an early-late kinetic, while glycoprotein
gE, encoded by ORF68, was detectable at 24 hpi, thereby exhibit-
ing late kinetics. In conclusion, cascade-like VZV protein expres-
sion could be observed in in vitro lytic VZV infection experiments
using cell-free virus.
Subcellular distribution of VZV proteins during lytic in vitro
infection. To determine the subcellular localization of viral pro-
teins in VZV-infected cells, uninfected MeWo cells were cocul-
turedwith VZV-infectedMeWo cells at a ratio of 50:1 for 48 h and
subsequently analyzed by IF. In total, the subcellular localization
of 46 of 71 (65%) unique VZV proteins could be determined.
Screening of subcellular localizations of individual VZV proteins
was analyzed in moderately sized syncytia at a rather late stage of
infection (Fig. 4 and Table 1).
Several representative VZV ORFs were further investigated by
high-resolution confocal microscopy (Fig. 5A). Several until now
poorly characterized ORFs, four of which are unique to VZV
(ORF1,ORF13,ORF32, andORF57), were analyzed together with
ORFs belonging to different localization and functional classes.
Capsid proteins (e.g., ORF20), proteins involved in capsid pack-
aging and maturation (e.g., ORF33, ORF33.5, and ORF55), and
proteins involved inDNA replication andmetabolism, aswas pro-
posed for ORF32 (32), were found primarily in the nucleus
(Fig. 5A and B). Several representatives of tegument proteins were
localized to either the nucleus (e.g., ORF64), both the cytoplasm
and center of syncytia/Golgi networks (e.g., ORF7, ORF9, ORF11,
ORF12, andORF22), or the nucleus and cytoplasm (e.g., ORF13),
probably depending on their role in primary or secondary envel-
opment. Glycoproteins, including ORF5 (gK) and the membrane
protein ORF1 (33), localized to the Golgi network and other
membranes. Similarly, a Golgi network- and membrane-associ-
ated localization was observed for ORF57, a poorly characterized
VZV protein (34).
FIG 2 Western blot analysis of VZV proteins expressed during lytic infection.
Lysates of uninfected () or infected () cells were prepared at 2 days postin-
fection and analyzed by Western blotting using VZV-specific MAbs raised
against the indicated ORFs. Molecular mass markers (in kDa) are shown on
the left.
FIG 3 Kinetics of VZV protein expression during lytic infection. Shown is a
time course analysis of VZV gene expression by Western blotting (WB) in in
vitro infection assays with cell-free virus. To monitor infection with cell-free
virus, ARPE-19 cells were spin inoculated at an MOI of 0.12. At the indicated
time points, cell lysates were prepared and analyzed by WB using MAbs di-
rected to VZV ORF4, ORF63, ORF8, ORF18, ORF48, ORF24, and ORF68.
Equal amounts of lysates were controlled with an actin-specific antibody.
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The results concur with knowledge of VZV biology reported in
the literature; for example, in comparison to cytoplasmic VZV
proteins, a higher percentage of nuclear VZV proteins was found
to be essential (P 0.031 by Fisher’s test) (Fig. 5B) (12). The data
suggest that VZV proteins involved in DNA replication and mor-
phogenesis are localized primarily in the nucleus of a lytically in-
fected cell.
VZV protein expression in herpes zoster lesions.Herpes zos-
ter is a VZV-induced disease characterized by a painful skin rash,
generally limited to one side of the body in a dermatomal pattern
(4). Detection of VZV DNA and antigens in zoster skin lesions by
PCR and immunohistochemistry (IHC), respectively, is of diag-
nostic value (35, 36). The availability of VZV ORF-specific MAbs
for IHC purposes is limited. A selection of the newly developed
VZV-specific MAbs was used to study the expression of the re-
spective VZV proteins in snap-frozen tissue sections of a herpes
zoster lesion (Fig. 6). Compared to the IgG2a isotype control, all
MAbs tested showed specific staining mainly at the border and
within the vesicular zoster lesion. The IHC staining pattern of the
newORF62- andORF63-specificMAbs resembled that of the pre-
viously established ORF62 (clone 8616)- and ORF63 (clone
9D12)-specific MAbs (31, 37). As reported previously, positive
staining of ORF4, ORF62, and ORF63 occurred in both the nuclei
and cytoplasm of epidermal and infundibular keratinocytes (38,
39). Overall, the data demonstrate the applicability of theseMAbs
for IHC purposes.
Cross-reactivity of anti-VZV MAbs with simian varicella vi-
rus proteins. SVV infection of rhesusmacaques represents a valu-
able nonhuman primate model to analyze the immunobiology
and pathogenesis of VZV infection (3, 17–19). However, aminor-
ity of SVV proteins have been studied until now. The newly devel-
oped collection ofVZV-specificMAbsmay provide novel tools for
FIG 4 Subcellular localization of VZV proteins in infected cells. VZV-infected cells were analyzed by indirect immunofluorescence at 2 days postinfection by
using the indicated VZVMAbs and an Alexa 488-conjugated secondary antibody. Nuclei were counterstained with DAPI, and pictures were obtained by using
a Leica fluorescence microscope. The size bar corresponds to 50 m.
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Orf0(S/L) 14.1 Membrane-associated protein NA UL56
Orf1 12.1 16–20 Tail-anchored membrane phosphoprotein Golgi/M None
Orf2 24.1 28 Membrane-associated phosphoprotein Golgi network None
Orf3 19.1 19 Potential role in gene expression NC UL55
Orf4 51.5 60 Transactivator N UL54
Orf5 38.6 55 Glycoprotein K Golgi/M UL53
Orf6 122.6 125 DNA helicase-primase complex N UL52
Orf7 28.2 35 Virion phosphoprotein Golgi network UL51
Orf8 44.8 50 dUTPase NC UL50
Orf9 32.9 35 50 Tegument protein C UL49
Orf9a 9.8 Glycoprotein N NA UL49a
Orf10 46.6 50 Transactivator NA UL48
Orf11 91.8 110 Tegument protein Golgi/M UL47
Orf12 74.3 80b Tegument protein Golgi/M UL46
Orf13 34.5 35 Thymidylate synthetase Golgi/M None
Orf14 61.4 70 Glycoprotein C Golgi network UL44
Orf15 44.5 Membrane protein NA UL43
Orf16 46.1 46 DNA polymerase-associated protein NC UL42
Orf17 51.4 Host shutoff protein NC UL41
Orf18 35.4 36 Ribonucleotide reductase (small SU) NA UL40
Orf19 86.8 90 Ribonucleotide reductase (large SU) NA UL39
Orf20 54 55 Capsid protein NC UL38
Orf21 115.8 120 Tegument protein Golgi/M UL37
Orf22 306.3 310b Tegument protein Golgi/M UL36
Orf23 24.4 35 Capsid protein N UL35
Orf24 23.8 32 60 Nuclear egress complex N UL34
Orf25 17.5 20 DNA packaging protein NC UL33
Orf26 65.7 80 Virion protein N UL32
Orf27 35.7 40 Nuclear egress complex N UL31
Orf28 134.1 DNA polymerase NA UL30
Orf29 132.1 SS-DNA binding protein NA UL29
Orf30 87 Virion protein NA UL28
Orf31 105.4 65 125 Glycoprotein B Golgi/M UL27
Orf32 16 18 20 Potential regulatory role in replication N None
Orf33 66 30/34 66/80b Protease, scaffold N UL26
ORF33.5 32.8 30/34b Scaffold N UL26.5
Orf34 65.2 Virion protein NA UL25
Orf35 29 Virion protein NA UL24
Orf36 37.8 38 TK NA UL23
Orf37 93.7 100 110 Glycoprotein H NA UL22
Orf38 60.4 Tegument protein NA UL21
Orf39 25.1 28 Membrane protein Golgi/M UL20
Orf40 155 155 Major capsid protein NA UL19
Orf41 34.4 35 Capsid protein NA UL18
Orf42 82.8 Terminase NA UL15
Orf43 74 Tegument protein NA UL17
Orf44 40.3 41b Tegument protein NC UL16
Orf45 40.2 DNA packaging protein NA UL15
Orf46 22.6 28 Minor tegument protein NA UL14
Orf47 57.4 60 S/T kinase C UL13
Orf48 61.3 65 DNase N UL12
Orf49 8.9 15 Myristylated virion protein Golgi/M UL11
Orf50 48.7 50–55 Glycoprotein M Golgi network UL10
Orf51 94.4 120b Origin binding protein NA UL9
Orf52 86.4 86 DNA helicase-primase complex NA UL8
Orf53 37.4 38 Potential role in mitochondrial function NA UL7
Orf54 86.8 90b Virion protein NA UL6
Orf55 98.9 DNA helicase-primase complex NC UL5
Orf56 21.8 22 35 Virion protein N UL4
(Continued on following page)
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the biochemical characterization of SVV. Because VZV and SVV
exhibit considerable sequence similarity at the protein level (Table
2), suggesting antigenic relatedness (17), we determined the po-
tential cross-reactivity of the VZV MAbs to the orthologous SVV
proteins. We analyzed all WB-reactive VZV MAbs using cell ly-
sates prepared from SVV-infected TRFs, and here, we show the
cross-reactivity of 20 anti-VZVMAbs with orthologous SVV pro-
teins (Fig. 7). The migration of most of the SVV proteins corre-
lated with the predicted molecular weight based on SVV genome
sequence data (Table 2) (17).However, a significant proportion of
detected SVV proteins appeared with a different size. The discrep-
ant SVV protein size detected byWBmay be caused by posttrans-
lational modification or proteolytic processing of the respective
viral proteins. The SVV proteins recognized by cross-reactive
VZVwere on average not more similar than undetected SVV pro-
teins (17), but the binding sites were highly conserved. The
epitopes of theMAbs directed against the ORF31 (gB) andORF60
(gL) glycoproteins were mapped by using 15-mer synthetic pep-
tides with an offset of 3 residues spotted onto nitrocellulosemem-
branes. In both viral proteins, the MAb-reactive epitopes were
linear peptides of 30 and 33 residues in length located within the
proteins’ cytoplasmic and extracellular domains, respectively. A
comparison of these VZV epitopes with the corresponding SVV
regions revealed striking sequence similarities of 76.6% (gB) and
78.8% (gL) between both varicelloviruses, which explains the
MAbs’ cross-reactivity. Moreover, the epitope recognized by the
anti-ORF60MAb seems to bewell conservedwithin all herpesviral
gL orthologs (40). In summary, our data show that many VZV-
specific MAbs are cross-reactive with SVV, thereby representing
new valuable tools for future research on both VZV and SVV
pathogenesis.
DISCUSSION
In this study, we present the first comprehensive characterization
ofVZVand, to some extent, SVVproteins expressed in vitro and in
situ. Our collection of VZV-specificMAbs covers 83% of the VZV
ORFeome. The fact that 40%of theVZVproteins were recognized
by using the sameMAb clone by bothWB and IF, and on occasion
by IHC, provides an internal quality control of the collection.
However, the true power of the collection lies in the availability of
differentMAb clones for each VZVORF, expressing different IgG
isotypes, recognizing different epitopes, and supporting different
methods, including biochemical, cell-biological, as well as immu-
nohistological studies. We were able to analyze the subcellular
distribution of 46 and the expression pattern of 57 VZV proteins,
with almost half of them being detected for the first time.
Previous approaches to systematically localize herpesviral pro-
teins in infected cells used transfection-based expression of tagged
recombinant viral proteins (41, 42). Since these proteins were ex-
pressed in a modified form and individually, which can influence
folding and binding to other viral proteins, localization may be
altered in the context of a natural lytic infection in vitro. In fact,
localization of several VZV proteins differed from that of HSV-1
orthologs, as reported by Salsman and colleagues, which is un-
likely to represent dissimilarities between these two alphaherpes-
virus species (41). A prominent example is the DNA helicase-
primase complex, consisting of ORF6, ORF52, and ORF55 in
VZV, and its corresponding orthologous HSV-1 complex, which
includes UL52, UL8, and UL5. In our study, the VZVORF6 com-
ponent was found to be nuclear, consistent with its function. In
contrast, its HSV-1 ortholog UL52 was documented to be pancy-
toplasmic under isolated expression conditions (41). Similarly,
the VZV DNase ORF48 was detected in the nucleus of infected
cells, whereas its HSV-1 ortholog UL12 was reported to be cyto-
plasmic. Thus, our antibody collection enables the direct detec-
tion of native and functional viral proteins, which represents the
best existing tool for the analysis of their expression, distribution,
and dynamics in the course of a lytic VZV infection.
Kinetics of VZV gene expression.VZVpropagates in vitro in a
cell-associated manner, forming multinucleated syncytia. Recent
advances in the production of cell-free VZV enabled the synchro-
nous infection of cells in vitro (25, 26). Using these reagents, we
showed that infection with cell-free VZV causes a lytic infection
cycle with a cascade-like protein expression profile of presumed
IE, E, and L viral genes. While in cell tracker experiments, expres-
sion of VZV ORF4 and ORF63 could be observed as early as 2 hpi









Orf57 8.1 12 Membrane-associated protein Golgi/M none
Orf58 25.1 30 Nuclear phosphoprotein N UL3
Orf59 34.4 35 Uracil DNA glycosylase N UL2
Orf60 17.6 35 Glycoprotein L NA UL1
Orf61 50.9 55c Transactivator N RL2
Orf62 140 140 Major transactivator NC RS1
Orf63 30.5 35c Cotransactivator NC US1
Orf64 19.9 20 Virion protein N US10
Orf65 11.4 20 Tegument phosphoprotein Golgi network US9
Orf66 43.7 48 S/T kinase NC US3
Orf67 39.4 70b Glycoprotein I Golgi/M US7
Orf68 70 100b Glycoprotein E Golgi/M US8
a Calculated and apparent molecular masses, function, and localization as determined by using our antibody collection and a herpes simplex virus 1 ortholog. N, nucleus (nuclear
localization includes the nuclear egress complex); C, cytoplasm; NC, majority in the nucleus; Golgi/M, Golgi network/membranes; NA, not analyzed; SU, subunit; TK,
thymidine kinase; SS-DNA, single-stranded DNA; S/T, serine/threonine.
b Possible degradation products or posttranslational processing/alternative translational initiation.
c Possible higher-molecular-mass products.
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and ORF63 being detected at around 6 hpi. ORF68 (gE), consid-
ered an L protein in other herpesviruses, was expressed rather
early in cell tracker experiments, as reported by Reichelt and col-
leagues (43), while it exhibited late kinetics in our study. Thus,
infectionwith cell-free VZV confirms cascade-like protein expres-
sion with immediate early, early, and late kinetics. Possibly, for-
mation of syncytia between the naive and inoculum cell leads to
untimely flooding of the naive cell with massive amounts of viral
proteins, leading to altered expression patterns. Alternatively, the
otherwise regulated kinetic expression is overruled by the high
virus load provided by the inoculum cells. Thus, cell-based prop-
agation of VZVmay more closely reflect the in vivo situation dur-
ing chickenpox and HZ.
Functional implications. VZV encodes 5 viral proteins
(ORF1, ORF2, ORF13, ORF32, and ORF57) that are missing in
the HSV-1 genome. Notably, these VZV ORFs are covered by our
VZV-specific MAb collection, which enabled us to study the lo-
calization of these viral proteins during lytic infection in vitro. Like
ORF1, a tail-anchored membrane protein (33), VZV ORF2 is re-
cruited to the Golgi network and potentially other membranes,
consistent with biochemical fractionation experiments (44). Sim-
ilarly, ORF13, a thymidylate synthetase (TS), was predominantly
detected in the center of syncytia and the Golgi network. Interest-
ingly, the interaction of ORF13 with ORF6 (20, 23), a component
of theDNAhelicase-primase complex, suggests a regulatory inter-
action between precursor synthesis and DNA encapsidation and
implies the partial localization of ORF13 to the nucleus. This ob-
servation was confirmed by confocal analysis. ORF32, however,
was found primarily in the nucleus, while a fraction may also be
found in the cytosol (32). The ORF32-specific MAb detected two
bands of 16 to 18 kDa, consistent with phosphorylation by the
VZV kinase ORF47 (32). Finally, ORF57 is found in the center of
syncytia, where theGolgi network resides. Since biochemical anal-
ysis classified ORF57 as a cytosolic protein (34), ORF57 may be
part of the VZV tegument recruited for secondary envelopment.
In yeast two-hybrid studies, ORF57 interacted with ORF39, a
membrane protein orthologous to HSV-1 UL20, and ORF9A, the
VZV glycoprotein gN (20, 23). Furthermore, ORF57 interacts
with additional proteins that are expected to be recruited to the
VZV virion based onHSV orthologs detected in extracellular viral
particles (45). These proteins include ORF10 (HSV-1 UL48),
ORF18 (UL40), ORF38 (UL21), ORF42 (UL15 terminase),
ORF46 (UL14), andORF62 (RS1) (20–23). Furthermore, with the
exception of ORF32, all viral proteins unique to VZV (ORF1,
ORF2, ORF13, and ORF57) were either exclusively or predomi-
nantly located to the Golgi network. We thus hypothesize that in
the course of secondary envelopment, most if not all of the unique
VZVproteins are incorporated into thematuring particle, thereby
determining critical steps of VZV pathogenesis in vivo.
The majority of the commercially available VZV-specific
MAbs (4 of 6) are directed toward the VZV glycoproteins gB, gE,
gH, and gI. In addition, polyclonal antibodies were generated for
VZV gC, gM, and gL. In contrast, no antibodies were available for
the type III transmembrane proteinORF39, the putative homolog
ofHSV-1UL20, or gK (ORF5). However, both VZVproteins have
been studied by using protein tagging (46, 47). Here we showed
that they localized to the center of syncytia/Golgi networks and
other membranes. ORF39 migrated according to its calculated
molecular weight, consistent with the absence of glycosylation. In
contrast to previous reports (48), migration of gKwasmuchmore
delayed, consistent with the addition of fully matured glycosyl
moieties at two acceptor sites. The discrepancy between these
studies could be explained by the use of different antibody re-
agents and their ability to gain access to their epitopes. While our
MAbmay recognize exclusively mature forms, immunoprecipita-
tion of tagged gK may have preselected an underglycosylated ver-
sion. Interestingly, the molecular weights of both VZV and SVV
FIG 5 Detailed analysis of localization and function of selected VZV proteins.
(A)At 2 days postinfection, VZV-infected cells were stainedwithMAbs against
the VZVORFs indicated in red and in parallel with antibodies specific to either
TGN46 (TGN) or laminB (La B), indicated in green. VZVMAbswere detected
by Alexa 594 (red)-conjugated secondary antibodies, and TGN/lamin BMAbs
were detected by Alexa 488 (green)-conjugated secondary antibodies. Nuclei
were counterstained with DAPI (blue), and pictures were obtained by using a
Leica SP5 confocal microscope. The size bar corresponds to 50 m. (B) Anal-
ysis of VZV ORFs based on their subcellular localization (panel A and Fig. 4)
and their function (top) or essentiality (bottom).Nuclear localization includes
the nuclear egress complex.
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gK observed by WB were similar, suggesting that our VZV/SVV
cross-reactive MAb recognizes the glycosylated mature form of
ORF5 in both VZV and SVV.
Two novelMAbs reactive to VZV gB (ORF31) and gL (ORF60)
were chosen for epitope analysis. The gB-specificMAb recognized
a single linear stretch of 30 residues enriched in positively charged
and hydrophobic residues. Similar to gB, gL and its interacting
partner gH are highly conserved among herpesviruses. VZV gH
and gL closely resemble their HSV orthologs (49). In general, both
glycoproteins are major targets of virus-neutralizing antibodies,
involved in inhibiting virus entry and infectivity (50). The epitope
analysis revealed that theVZVgL-specificMAbdecorated a region
highly conserved between gL orthologs (40), suggesting that this
MAb will likely recognize gL orthologs of other members of the
herpesvirus family. However, the same region is particularly im-
portant for the interaction of gL with gH, the transport of the
complex to the cell surface, and its function during entry of HSV
(51). It may be expected that none of the tested MAbs will show a
neutralizing capacity. In the case of gB, it recognizes the cytoplas-
mic tail, while in the case of gL, the epitope is most likely hidden
when the gH/gL complex has formed and is exposed on the cell
surface. In line with this, a recently described recombinant MAb
with a high capacity to neutralize VZV recognized the VZV gH/gL
protein complex but not individual gH or gL proteins (52). The
remainingMAbs of the collection that are still incompletely char-
acterized may harbor the potential to neutralize VZV infection.
Cross-reactivity of anti-VZV MAbs with SVV. Due to the
highly restricted host range of VZV compared to that of HSV,
detailed analyses of the pathogenesis of VZV in an appropriate
experimental animal model are lacking. Recently, the nonhuman
primate varicellovirus SVV has received great attention in studies
of varicella and herpes zoster pathology in monkeys (53). How-
FIG 6 VZV protein expression in herpes zoster skin lesions. Frozen sections of suspected herpes zoster skin lesions and healthy control skin were processed for
immunohistochemistry using VZVMAbs directed to ORF4, ORF21, ORF62, ORF63, or ORF66. The previously established anti-VZVMAbs directed to ORF62
(clone 8616) andORF63 (clone 9D12)were included as positive controls. AMAb (IgG2a subclass) directed to an irrelevant antigenwas used as a negative control.
To present the overall histology of the herpes zoster and control skin, staining with hematoxylin and eosin is shown. Antibody binding was visualized by using
the avidin-biotin complex system and 3-amino-9-ethylcarbazole substrate (red).





similarity to VZVCalculated Apparent
ORF3 19.7 20 63.7
ORF5 42 55 59.3
ORF7 25.3 30 72.9
ORF8 44.9 45 38.2
ORF9 33.2 20 59.4
ORF14 60.5 72 43.8
ORF20 52.9 53 60.5
ORF27 35.4 35 74.4
ORF31 104 55 60 125 75.4
ORF33/33.5 65.1 30a 64.4
ORF36 37.9 30 52.3
ORF37 96.8 97 55.5
ORF39 25.4 20 53.1
ORF41 34.3 32 70.5
ORF54 83.5 85 59.5
ORF60 20.2 17 26a 43.5
ORF62 136.8 140 160 58.0
ORF63 29.3 40 52.0
ORF65 9.0 17 30a 49.0
ORF68 67.6 65 47.0
a Possible higher-molecular-mass products.
b The sequence similarity was previously described by Gray (17).
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ever, due to the lack of specific reagents, SVV protein characteris-
tics remain ill defined. Western blot analysis revealed that 20 SVV
proteins were recognized by the MAbs developed for VZV or-
thologs. This reflects the sequence similarity between VZV and
SVVORFs, which varies between 27 and 75% amino acid identity
(17). The predicted size for SVV proteins is based on published
amino acid sequences.However, while attempting to clone certain
open reading frames of the virus, we came across sequences that
differ from the published SVV sequence. In the case of ORF65, the
DNA sequence of this gene contains mistakes leading to a frame-
shift and, thus, a premature stop codon in the published sequence.
The molecular mass of SVV ORF65 was 7 kDa higher than ex-
pected based on SVV genome sequence data (54). While, in gen-
eral, the published sequence is correct, the SVV genomic se-
quences may need correction in certain regions. In summary,
since very few SVV-specific antibodies have been available so far
(18, 55, 56), our MAbs will facilitate the analysis of SVV in non-
human primate models and provide novel insights into SVV
pathogenesis.
In summary, the current study presents the generation of a
comprehensive set of VZV-specific MAbs that were used here for
detailed analyses of themajority of viral proteins expressed during
VZV infection in vitro and in situ. The data provide novel insights
into the potential function ofmany uncharacterizedVZVproteins
and tools to systematically investigate varicellovirus pathogenesis
in future studies, which are mandatory to develop new interven-
tion strategies to prevent and treat varicellovirus infections.
ACKNOWLEDGMENTS
This work was supported by the EU FP6 INCO-CT-2006-026278 grant,
Establishment of High-Throughput Monoclonal Antibody Production
and Hybridoma Bank (CAPRI) (S.J. and J.H.); the EU FP7 REGPOT
229585 grant, Center for Antibody Production Rijeka: Upgrading the
Central Research and Service Infrastructure for the South Eastern Region
of Europe (CAPRI2010) (S.J.); and the Bayerisches Staatsministerium für
Wissenschaft, Forschung und Kunst (Baygene) (J.H.).
We thank Dietlind Rose, Manuel Endesfelder, Filip Markovic´, and
Danijela Baždaric´ for technical assistance and R. M. Verdijk and E. P.
Prens (Erasmus MC) for providing the herpes zoster and human control
skin specimens, respectively.
REFERENCES
1. Arvin AM. 1996. Varicella-zoster virus. Clin. Microbiol. Rev. 9:361–381.
2. Arvin AM. 2001. Varicella-zoster virus: molecular virology and virus-host
interactions. Curr. Opin. Microbiol. 4:442–449.
3. Moffat J, Ku CC, Zerboni L, Sommer M, Arvin A. 2007. VZV:
pathogenesis and the disease consequences of primary infection, p
675–688. In Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS,
FIG 7 Cross-reactivity of VZV-specific antibodies with SVV proteins in Western blots. (A) To determine if the VZV-specific MAbs recognized SVV proteins,
protein lysates were generated frommock- and SVV-infectedmonkey cells at 48 h postinfection and analyzed byWestern blotting usingMAbs raised against the
indicatedVZVORFs.Molecularmassmarkers (in kDa) are shown on the left. (B) Synthetic peptides covering the domain ofORF31/gB (residues 814 to 931) and
ORF60/gL (residues 37 to 160, shown together with its interacting glycoprotein gH), previously used as immunogens, were synthesized as 15-mers with an offset
of 3 residues and coupled to cellulose membranes. Membranes were incubated with ORF-specific antibodies. The topology of these membrane proteins is
depicted graphically; the sequence of reactive peptides is shown in red. The epitope region identified in VZV ORF31/gB and ORF60/gL (top) is aligned with the
amino acid sequence of the respective ORF31 and ORF60 of SVV (bottom). Asterisks represent conserved but not identical amino acids.
Lenac Roviš et al.
6952 jvi.asm.org Journal of Virology
Roizman B, Whitley R, Yamanishi K (ed), Human herpesviruses: biol-
ogy, therapy, and immunoprophylaxis. Cambridge University Press,
Cambridge, United Kingdom.
4. Cohen JI. 2007. VZV: molecular basis of persistence (latency and reacti-
vation), p 689–699. InArvin A, Campadelli-FiumeG,Mocarski E,Moore
PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesviruses: bi-
ology, therapy, and immunoprophylaxis. Cambridge University Press,
Cambridge, United Kingdom.
5. Arvin A, Abendroth A. 2007. VZV: immunobiology and host response, p
700–712. In Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roiz-
manB,Whitley R, Yamanishi K (ed),Humanherpesviruses: biology, ther-
apy, and immunoprophylaxis. Cambridge University Press, Cambridge,
United Kingdom.
6. Gilden D, Mahalingam R, Nagel MA, Pugazhenthi S, Cohrs RJ. 2011.
The neurobiology of varicella zoster virus infection. Neuropathol. Appl.
Neurobiol 37:441–463.
7. Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I,
Rota MC, de Melker H, Mossong J, Slacikova M, Tischer A, Andrews N,
Berbers G, Gabutti G, Gay N, Jones L, Jokinen S, Kafatos G, de Aragon
MV, Schneider F, Smetana Z, Vargova B, Vranckx R, Miller E. 2007.
The comparative sero-epidemiology of varicella zoster virus in 11 coun-
tries in the European region. Vaccine 25:7866–7872.
8. Gershon AA. 2007. Varicella-zoster vaccine, p 1262–1273. In Arvin A,
Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Ya-
manishi K (ed), Human herpesviruses: biology, therapy, and immu-
noprophylaxis. Cambridge University Press, Cambridge, United King-
dom.
9. Roizman B, Campadelli-Fiume G. 2007. Alphaherpes viral genes and
their functions, p 70–92. In Arvin A, Campadelli-Fiume G, Mocarski E,
Moore PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesvi-
ruses: biology, therapy, and immunoprophylaxis. Cambridge University
Press, Cambridge, United Kingdom.
10. Cohen JI. 2010. The varicella-zoster virus genome. Curr. Top. Microbiol.
Immunol. 342:1–14.
11. Baines JD, Pellett PE. 2007. Genetic comparison of human alphaherpes-
virus genomes, p 61–69. In Arvin A, Campadelli-Fiume G, Mocarski E,
Moore PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesvi-
ruses: biology, therapy, and immunoprophylaxis. Cambridge University
Press, Cambridge, United Kingdom.
12. Zhang Z, Selariu A, Warden C, Huang G, Huang Y, Zaccheus O, Cheng
T, Xia N, Zhu H. 2010. Genome-wide mutagenesis reveals that ORF7 is a
novel VZV skin-tropic factor. PLoS Pathog. 6:e1000971. doi:10.1371
/journal.ppat.1000971.
13. Kaufer BB, Smejkal B, Osterrieder N. 2010. The varicella-zoster virus
ORFS/L (ORF0) gene is required for efficient viral replication and con-
tains an element involved in DNA cleavage. J. Virol. 84:11661–11669.
14. Chen JJ, Zhu Z, Gershon AA, Gershon MD. 2004. Mannose 6-phosphate
receptor dependence of varicella zoster virus infection in vitro and in the
epidermis during varicella and zoster. Cell 119:915–926.
15. Myers MG, Connelly BL. 1992. Animal models of varicella. J. Infect. Dis.
166(Suppl 1):S48–S50.
16. Ku CC, Besser J, Abendroth A, Grose C, Arvin AM. 2005. Varicella-
zoster virus pathogenesis and immunobiology: new concepts emerging
from investigations with the SCIDhu mouse model. J. Virol. 79:2651–
2658.
17. Gray WL. 2010. Simian varicella virus: molecular virology. Curr. Top.
Microbiol. Immunol. 342:291–308.
18. Gray WL, Mullis LB, Soike KF. 2001. Expression of the simian varicella
virus glycoprotein E. Virus Res. 79:27–37.
19. Messaoudi I, Barron A, Wellish M, Engelmann F, Legasse A, Planer S,
Gilden D, Nikolich-Zugich J, Mahalingam R. 2009. Simian varicella
virus infection of rhesus macaques recapitulates essential features of vari-
cella zoster virus infection in humans. PLoS Pathog. 5:e1000657. doi:10
.1371/journal.ppat.1000657.
20. Uetz P, Dong YA, Zeretzke C, Atzler C, Baiker A, Berger B, Rajagopala
SV, Roupelieva M, Rose D, Fossum E, Haas J. 2006. Herpesviral protein
networks and their interaction with the human proteome. Science 311:
239–242.
21. Cagney G, Uetz P, Fields S. 2000. High-throughput screening for pro-
tein-protein interactions using two-hybrid assay. Methods Enzymol. 328:
3–14.
22. Fossum E, Friedel CC, Rajagopala SV, Titz B, Baiker A, Schmidt T,
Kraus T, Stellberger T, Rutenberg C, Suthram S, Bandyopadhyay S,
Rose D, von Brunn A, Uhlmann M, Zeretzke C, Dong YA, Boulet H,
Koegl M, Bailer SM, Koszinowski U, Ideker T, Uetz P, Zimmer R, Haas
J. 2009. Evolutionarily conserved herpesviral protein interaction net-
works. PLoS Pathog. 5:e1000570. doi:10.1371/journal.ppat.1000570.
23. Stellberger T, Hauser R, Baiker A, Pothineni VR, Haas J, Uetz P. 2010.
Improving the yeast two-hybrid systemwith permutated fusions proteins:
the varicella zoster virus interactome. Proteome Sci. 8:8. doi:10.1186/1477
-5956-8-8.
24. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. 1974. Live vaccine
used to prevent the spread of varicella in children in hospital. Lancet
ii:1288.
25. Schmidt-Chanasit J, Bleymehl K, Rabenau HF, Ulrich RG, Cinatl J, Jr,
Doerr HW. 2008. In vitro replication of varicella-zoster virus in human
retinal pigment epithelial cells. J. Clin. Microbiol. 46:2122–2124.
26. Harper DR, Mathieu N, Mullarkey J. 1998. High-titre, cryostable cell-
free varicella zoster virus. Arch. Virol. 143:1163–1170.
27. Mahalingam R, Wellish M, White T, Soike K, Cohrs R, Kleinschmidt-
DeMasters BK, Gilden DH. 1998. Infectious simian varicella virus ex-
pressing the green fluorescent protein. J. Neurovirol. 4:438–444.
28. Ott M, Tascher G, Hassdenteufel S, Zimmermann R, Haas J, Bailer SM.
2011. Functional characterization of the essential tail anchor of the herpes
simplex virus type 1 nuclear egress protein pUL34. J. Gen. Virol. 92:2734–
2745.
29. Remeijer L, Duan R, van Dun JM, Wefers Bettink MA, Osterhaus AD,
Verjans GM. 2009. Prevalence and clinical consequences of herpes sim-
plex virus type 1 DNA in human cornea tissues. J. Infect. Dis. 200:11–19.
30. Verjans GM, Hintzen RQ, van Dun JM, Poot A, Milikan JC, Laman JD,
Langerak AW, Kinchington PR, Osterhaus AD. 2007. Selective retention
of herpes simplex virus-specific T cells in latently infected human trigem-
inal ganglia. Proc. Natl. Acad. Sci. U. S. A. 104:3496–3501.
31. Kennedy PG, Grinfeld E, Bontems S, Sadzot-Delvaux C. 2001. Varicella-
zoster virus gene expression in latently infected rat dorsal root ganglia.
Virology 289:218–223.
32. Reddy SM, Cox E, Iofin I, Soong W, Cohen JI. 1998. Varicella-zoster
virus (VZV) ORF32 encodes a phosphoprotein that is posttranslationally
modified by the VZV ORF47 protein kinase. J. Virol. 72:8083–8088.
33. Koshizuka T, Sadaoka T, Yoshii H, Yamanishi K, Mori Y. 2008. Vari-
cella-zoster virusORF1 gene product is a tail-anchoredmembrane protein
localized to plasma membrane and trans-Golgi network in infected cells.
Virology 377:289–295.
34. Cox E, Reddy S, Iofin I, Cohen JI. 1998. Varicella-zoster virus ORF57,
unlike its pseudorabies virus UL3.5 homolog, is dispensable for viral rep-
lication in cell culture. Virology 250:205–209.
35. NuovoGJ. 2006. The surgical and cytopathology of viral infections: utility
of immunohistochemistry, in situ hybridization, and in situ polymerase
chain reaction amplification. Ann. Diagn. Pathol. 10:117–131.
36. Muraki R, Baba T, Iwasaki T, Sata T, Kurata T. 1992. Immunohisto-
chemical study of skin lesions in herpes zoster. Virchows Arch. A Pathol.
Anat. Histopathol. 420:71–76.
37. Ouwendijk WJ, Flowerdew SE, Wick D, Horn AK, Sinicina I, Strupp M,
Osterhaus AD, Verjans GM, Hufner K. 2012. Immunohistochemical
detection of intra-neuronal VZVproteins in snap-frozen human ganglia is
confounded by antibodies directed against blood group A1-associated an-
tigens. J. Neurovirol. 18:172–180.
38. Nikkels AF, Debrus S, Sadzot-Delvaux C, Piette J, Rentier B, Pierard
GE. 1995. Immunohistochemical identification of varicella-zoster virus
gene 63-encoded protein (IE63) and late (gE) protein on smears and
cutaneous biopsies: implications for diagnostic use. J. Med. Virol. 47:342–
347.
39. Huch JH, Cunningham AL, Arvin AM, Nasr N, Santegoets SJ, Slobe-
dman E, Slobedman B, Abendroth A. 2010. Impact of varicella-zoster
virus on dendritic cell subsets in human skin during natural infection. J.
Virol. 84:4060–4072.
40. Fan Q, Lin E, Spear PG. 2009. Insertional mutations in herpes simplex
virus type 1 gL identify functional domains for associationwith gH and for
membrane fusion. J. Virol. 83:11607–11615.
41. Salsman J, Zimmerman N, Chen T, Domagala M, Frappier L. 2008.
Genome-wide screen of three herpesviruses for protein subcellular local-
ization and alteration of PML nuclear bodies. PLoS Pathog. 4:e1000100.
doi:10.1371/journal.ppat.1000100.
42. Sander G, Konrad A, Thurau M, Wies E, Leubert R, Kremmer E, Dinkel
H, Schulz T, Neipel F, Sturzl M. 2008. Intracellular localization map of
human herpesvirus 8 proteins. J. Virol. 82:1908–1922.
Global Analysis of VZV Proteins
June 2013 Volume 87 Number 12 jvi.asm.org 6953
43. Reichelt M, Brady J, Arvin AM. 2009. The replication cycle of varicella-
zoster virus: analysis of the kinetics of viral protein expression, genome
synthesis, and virion assembly at the single-cell level. J. Virol. 83:3904–
3918.
44. Sato H, Pesnicak L, Cohen JI. 2002. Varicella-zoster virus open reading
frame 2 encodes a membrane phosphoprotein that is dispensable for viral
replication and for establishment of latency. J. Virol. 76:3575–3578.
45. Loret S, Guay G, Lippe R. 2008. Comprehensive characterization of
extracellular herpes simplex virus type 1 virions. J. Virol. 82:8605–8618.
46. Govero J, Hall S, Heineman TC. 2007. Intracellular localization of vari-
cella-zoster virus ORF39 protein and its functional relationship to glyco-
protein K. Virology 358:291–302.
47. Hall SL, Govero JL, Heineman TC. 2007. Intracellular transport and
stability of varicella-zoster virus glycoprotein K. Virology 358:283–290.
48. Mo C, Suen J, Sommer M, Arvin A. 1999. Characterization of varicella-
zoster virus glycoprotein K (open reading frame 5) and its role in virus
growth. J. Virol. 73:4197–4207.
49. Grose C, Carpenter JE, Jackson W, Duus KM. 2010. Overview of vari-
cella-zoster virus glycoproteins gC, gH and gL. Curr. Top. Microbiol. Im-
munol. 342:113–128.
50. Vleck SE, Oliver SL, Reichelt M, Rajamani J, Zerboni L, Jones C,
Zehnder J, Grose C, Arvin AM. 2010. Anti-glycoprotein H antibody
impairs the pathogenicity of varicella-zoster virus in skin xenografts in the
SCID mouse model. J. Virol. 84:141–152.
51. Chowdary TK, Cairns TM, Atanasiu D, Cohen GH, Eisenberg RJ,
Heldwein EE. 2010. Crystal structure of the conserved herpesvirus fusion
regulator complex gH-gL. Nat. Struct. Mol. Biol. 17:882–888.
52. Birlea M, Owens GP, Eshleman EM, Ritchie A, Traktinskiy I, Bos N,
Seitz S, Yevgeniy A, Mahalingam R, Gilden D, Cohrs RJ. 2013. Human
anti-varicella-zoster virus (VZV) recombinantmonoclonal antibody pro-
duced after Zostavax immunization recognizes gH/gL complex and neu-
tralizes VZV infection. J. Virol. 87:415–421.
53. Mahalingam R, Gilden DH. 2007. Simian varicella virus, p 1043–1050. In
ArvinA,Campadelli-FiumeG,MocarskiE,MoorePS,RoizmanB,WhitleyR,
Yamanishi K (ed),Humanherpesviruses: biology, therapy, and immunopro-
phylaxis. Cambridge University Press, Cambridge, United Kingdom.
54. Gray WL, Starnes B, White MW, Mahalingam R. 2001. The DNA
sequence of the simian varicella virus genome. Virology 284:123–130.
55. Ashburn CV, Gray WL. 2002. Expression of the simian varicella virus
glycoprotein L and H. Arch. Virol. 147:335–348.
56. Mueller NH, Bos NL, Seitz S, Wellish M, Mahalingam R, Gilden D,
Cohrs RJ. 2012. Recombinant monoclonal antibody recognizes a unique
epitope on varicella-zoster virus immediate-early 63 protein. J. Virol. 86:
6345–6349.
Lenac Roviš et al.
6954 jvi.asm.org Journal of Virology
